US7947A
(en)
|
|
1851-02-25 |
|
Bellows fob musical instruments |
US646A
(en)
|
|
1838-03-21 |
|
Improvement in furnaces for smelting iron with anthracite |
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4411993A
(en)
|
1981-04-29 |
1983-10-25 |
Steven Gillis |
Hybridoma antibody which inhibits interleukin 2 activity
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
USRE32011E
(en)
|
1981-12-14 |
1985-10-22 |
Scripps Clinic And Research Foundation |
Ultrapurification of factor VIII using monoclonal antibodies
|
JPS58117537A
(ja)
|
1982-01-06 |
1983-07-13 |
Toray Ind Inc |
感光性樹脂組成物
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
US4737462A
(en)
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US4902614A
(en)
|
1984-12-03 |
1990-02-20 |
Teijin Limited |
Monoclonal antibody to human protein C
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5011912A
(en)
|
1986-12-19 |
1991-04-30 |
Immunex Corporation |
Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
|
JPH01171495A
(ja)
|
1987-12-25 |
1989-07-06 |
Ajinomoto Co Inc |
モノクローナル抗体及びそれを用いる定量法
|
US5750375A
(en)
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
WO1990014363A1
(en)
|
1989-05-19 |
1990-11-29 |
Amgen Inc. |
Metalloproteinase inhibitor
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
CA2090126C
(en)
|
1990-08-02 |
2002-10-22 |
John W. Schrader |
Methods for the production of proteins with a desired function
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
EP0546073B1
(en)
|
1990-08-29 |
1997-09-10 |
GenPharm International, Inc. |
production and use of transgenic non-human animals capable of producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化b−b10
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
US6153407A
(en)
|
1992-07-28 |
2000-11-28 |
Beth Israel Deaconess Medical Center |
Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
GB9223377D0
(en)
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
ES2201076T3
(es)
|
1993-03-19 |
2004-03-16 |
The Johns Hopkins University School Of Medicine |
Factor-8 de diferenciacion del crecimiento.
|
US6607884B1
(en)
|
1993-03-19 |
2003-08-19 |
The Johns Hopkins University School Of Medicine |
Methods of detecting growth differentiation factor-8
|
US6465239B1
(en)
|
1993-03-19 |
2002-10-15 |
The John Hopkins University School Of Medicine |
Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
US5863738A
(en)
|
1994-04-29 |
1999-01-26 |
Creative Biomolecules, Inc. |
Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
|
US5545616A
(en)
|
1994-09-22 |
1996-08-13 |
Genentech, Inc. |
Method for predicting and/or preventing preterm labor
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
IE80468B1
(en)
|
1995-04-04 |
1998-07-29 |
Elan Corp Plc |
Controlled release biodegradable nanoparticles containing insulin
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
ES2301198T3
(es)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
Polipeptidos artificiales de anticuerpos.
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
DK1129190T4
(en)
|
1998-11-13 |
2017-04-03 |
Immunex Corp |
Human TSLP DNA and polypeptides
|
MXPA01007366A
(es)
|
1999-01-21 |
2002-06-04 |
Metamorphix Inc |
Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
|
GB9928787D0
(en)
|
1999-12-03 |
2000-02-02 |
Medical Res Council |
Direct screening method
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
AU2001265198A1
(en)
|
2000-06-01 |
2001-12-11 |
Amgen Inc. |
Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
|
US6812339B1
(en)
|
2000-09-08 |
2004-11-02 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
GB0025144D0
(en)
|
2000-10-13 |
2000-11-29 |
Medical Res Council |
Concatenated nucleic acid sequences
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
EP1406929A2
(en)
|
2001-07-18 |
2004-04-14 |
MERCK PATENT GmbH |
Glycoprotein vi fusion proteins
|
GB0209896D0
(en)
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
EP2272864A3
(en)
|
2002-12-20 |
2011-02-16 |
Amgen Inc. |
Binding agents which inhibit myostatin
|
US20040202995A1
(en)
|
2003-04-09 |
2004-10-14 |
Domantis |
Nucleic acids, proteins, and screening methods
|
CN1829532A
(zh)
|
2003-06-02 |
2006-09-06 |
惠氏公司 |
肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
|
ES2655435T3
(es)
|
2003-09-12 |
2018-02-20 |
Amgen Inc. |
Formulación de disolución rápida de cinacalcet
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
JP4870569B2
(ja)
|
2003-11-13 |
2012-02-08 |
ハンミ ホールディングス カンパニー リミテッド |
免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
|
US7514534B2
(en)
|
2003-11-19 |
2009-04-07 |
Dyax Corp. |
Metalloproteinase-binding proteins
|
US20050272637A1
(en)
|
2004-04-22 |
2005-12-08 |
Oregon Health & Science University |
Compositions and methods for modulating signaling mediated by IGF-1 receptor and erbB receptors
|
CN1997356A
(zh)
|
2004-04-23 |
2007-07-11 |
安姆根有限公司 |
持续释放制剂
|
US7575751B2
(en)
|
2004-04-27 |
2009-08-18 |
Research Development Foundation |
Activin-A mutants
|
CA2574777C
(en)
|
2004-07-23 |
2015-09-01 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
CA2575563A1
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
EA011879B1
(ru)
|
2004-09-24 |
2009-06-30 |
Эмджин Инк. |
МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
|
EP1824886B1
(en)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Fully human monoclonal antibodies to il-13
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
AR062247A1
(es)
|
2005-03-08 |
2008-10-29 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos anti-ctla-4
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
JP2008539241A
(ja)
|
2005-04-25 |
2008-11-13 |
ファイザー インコーポレイティッド |
ミオスタチンに対する抗体
|
CA2621371C
(en)
*
|
2005-09-07 |
2018-05-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
CL2007002567A1
(es)
*
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
RS52537B
(en)
|
2006-12-18 |
2013-04-30 |
Acceleron Pharma Inc. |
ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
|
TW201627320A
(zh)
|
2007-02-02 |
2016-08-01 |
艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
US7947646B2
(en)
*
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
ES2449753T3
(es)
|
2007-03-19 |
2014-03-21 |
National Research Council Of Canada |
Proteínas de fusión que comprenden dos dominios de unión tgf-beta
|
EP2207562B1
(en)
*
|
2007-09-18 |
2017-05-31 |
Acceleron Pharma, Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
CA2729100C
(en)
|
2008-06-26 |
2018-01-02 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
TW201803586A
(zh)
|
2008-08-14 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
BRPI0920962A2
(pt)
*
|
2008-11-26 |
2016-07-12 |
Amgen Inc |
variantes de polipeptídeos receptores de activina iib e usos dos mesmos
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
CA2993053A1
(en)
|
2009-04-27 |
2010-11-04 |
Novartis Ag |
Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
|
EP3345921A1
(en)
|
2009-06-08 |
2018-07-11 |
Acceleron Pharma Inc. |
Use of anti-actriib antibodies for increasing thermogenic adipocytes
|
JP6211767B2
(ja)
|
2009-09-09 |
2017-10-11 |
アクセルロン ファーマ, インコーポレイテッド |
ActRIIbアンタゴニストならびにその投薬および使用
|
WO2011085165A2
(en)
*
|
2010-01-08 |
2011-07-14 |
The Brigham And Women's Hospital, Inc. |
Ca-125 immune complexes as biomarkers of ovarian cancer
|
CA2794513A1
(en)
*
|
2010-03-31 |
2011-10-06 |
Aeterna Zentaris Gmbh |
Perifosine and capecitabine as a combined treatment for cancer
|
CA2817008A1
(en)
*
|
2010-11-08 |
2012-05-18 |
Acceleron Pharma Inc. |
Actriia binding agents and uses thereof
|
EA201491231A8
(ru)
*
|
2011-12-19 |
2015-01-30 |
Амген Инк. |
Варианты полипептидов рецептора активина и их применение
|
EP2802308A1
(en)
*
|
2012-01-13 |
2014-11-19 |
Allergan, Inc. |
Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
CN107074931A
(zh)
|
2014-06-13 |
2017-08-18 |
圣塔玛丽亚生物疗法公司 |
经配制的受体多肽和相关方法
|